Johnson & Johnson (JNJ) Beats Q1 Earnings And Revenue Estimates

Johnson & Johnson (JNJ - Free Report) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.30 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 12.12%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $1.81 per share when it actually produced earnings of $1.86, delivering a surprise of 2.76%.

Dna, Genetic Material, Helix, Proteins, Biology

Image Source: Unsplash

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Johnson & Johnson, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $22.32 billion for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 2.31%. This compares to year-ago revenues of $20.69 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Johnson & Johnson shares have added about 3.1% since the beginning of the year versus the S&P 500's gain of 11.4%.

What's Next for Johnson & Johnson?

While Johnson & Johnson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

1 2
View single page >> |

Disclaimer: Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.